Autopsy report · NCT01819142

AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers

“Protocol study design was re-worked in collaboration with CMS”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 9 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Cytomedix

Sponsor type

Industry

Conditions

Pressure Ulcer

Interventions

AutoloGel

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
  “Study was redeveloped into a new protocol” (66% match in meaning)
• Bacteriophage Therapy in Patients With Prosthetic Joint Infections
  “Changes to protocol design” (62% match in meaning)
• The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study
  “Protocol design under review.” (57% match in meaning)
• Cell Therapy in Dilated Cardiomyopathy: Observational Study
  “finish study as protocol” (57% match in meaning)
• Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
  “On 05/08/12, team working on revising protocol and re-open study under version 2.0” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.